Safety profile of recombinant factor VIIa
HR Roberts, DM Monroe III, M Hoffman - Seminars in hematology, 2004 - Elsevier
Recombinant factor VIIa (rFVIIa; NovoSeven®, Novo Nordisk, Bagsvaerd, Denmark) has
been used for many years in the successful management of bleeding episodes in patients
with hemophilia and inhibitors. More recently, rFVIIa has also shown considerable success
as a hemostatic agent in trauma and surgery patients without pre-existing coagulopathy.
Despite extensive and varied usage of rFVIIa, the incidence of serious adverse events
associated with its use is less than 1%; however, there remain concerns regarding the …
been used for many years in the successful management of bleeding episodes in patients
with hemophilia and inhibitors. More recently, rFVIIa has also shown considerable success
as a hemostatic agent in trauma and surgery patients without pre-existing coagulopathy.
Despite extensive and varied usage of rFVIIa, the incidence of serious adverse events
associated with its use is less than 1%; however, there remain concerns regarding the …